Enliven Therapeutics, Inc. (ELVN)
NASDAQ: ELVN · Real-Time Price · USD
58.82
+0.76 (1.31%)
At close: Aug 14, 2026, 4:00 PM EDT
58.94
+0.12 (0.21%)
After-hours: Aug 14, 2026, 7:34 PM EDT

Enliven Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Income
-124.41-119.66-104.55-82.23-38.79-24.76
Net Income
-105.93-103.69-89.02-71.58-37.66-24.74
Earnings Per Share
-1.67-1.83-1.89-2.01-12.05-3.17
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
895.16462.62313.44253.1575.54110.02
Total Debt
1.510.4-0.340.60.16
Net Cash (Debt)
893.65462.22313.44252.8174.94109.87
Net Cash Growth
82.41%47.47%23.98%237.37%-31.79%-15.66%
Net Cash Per Share
14.108.166.667.1123.9914.06

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-66.94-70.3-73.19-61.27-32.08-19.13
Capital Expenditures
-0.1-0.16-0.04-0.15-0.61-0.19
Free Cash Flow
-67.04-70.46-73.24-61.42-32.69-19.33
Free Cash Flow Growth
------

Valuation

Selected indicators aren't available for this stock.